- Home
- CRDF vs HBB Comparison
CRDF vs HBB Comparison
Compare CRDF & HBB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- HBB
- Stock Information
- Founded
- CRDF 1999
- HBB 1904
- Country
- CRDF United States
- HBB United States
- Employees
- CRDF N/A
- HBB N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- HBB Home Furnishings
- Sector
- CRDF Health Care
- HBB Consumer Discretionary
- Exchange
- CRDF Nasdaq
- HBB Nasdaq
- Market Cap
- CRDF 288.7M
- HBB N/A
- IPO Year
- CRDF N/A
- HBB 2017
- Fundamental
- Price
- CRDF $3.19
- HBB $19.67
- Analyst Decision
- CRDF Strong Buy
- HBB
- Analyst Count
- CRDF 4
- HBB 0
- Target Price
- CRDF $12.00
- HBB N/A
- AVG Volume (30 Days)
- CRDF 1.1M
- HBB 36.9K
- Earning Date
- CRDF 05-01-2025
- HBB 05-06-2025
- Dividend Yield
- CRDF N/A
- HBB 2.35%
- EPS Growth
- CRDF N/A
- HBB 22.33
- EPS
- CRDF N/A
- HBB 2.20
- Revenue
- CRDF $683,000.00
- HBB $654,693,000.00
- Revenue This Year
- CRDF N/A
- HBB N/A
- Revenue Next Year
- CRDF N/A
- HBB N/A
- P/E Ratio
- CRDF N/A
- HBB $8.85
- Revenue Growth
- CRDF 39.96
- HBB 4.65
- 52 Week Low
- CRDF $2.01
- HBB $14.34
- 52 Week High
- CRDF $6.38
- HBB $31.78
- Technical
- Relative Strength Index (RSI)
- CRDF 34.89
- HBB 49.50
- Support Level
- CRDF $3.65
- HBB $18.98
- Resistance Level
- CRDF $3.88
- HBB $20.15
- Average True Range (ATR)
- CRDF 0.25
- HBB 0.89
- MACD
- CRDF -0.07
- HBB -0.13
- Stochastic Oscillator
- CRDF 8.21
- HBB 39.78
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").